Hexavalent vaccines

Price for one auto-disable (AD) syringe and needle 

• As of October 2025, the UNICEF procurement price for 2026 ranges from US$ 0.023 to US$ 0.046, depending on supplier and product.^{Go to footnote 11}
• The 2026 PAHO Revolving Fund for Access to Vaccines price ranges from US$ 0.03 to US$ 0.04, depending on supplier and product.^{Go to footnote 22} 

Price for one 5-litre safety box  

• The UNICEF procurement price for 2026 ranges from US$ 0.375 to US$ 0.860, depending on supplier and product.^{Go to footnote 33}
• The 2026 PAHO Revolving Fund for Access to Vaccines price ranges from US$ 0.41 to US$ 0.47, depending on supplier and product.^{Go to footnote 22} 

Each 5-litre safety box can hold around 100 syringes.

Hexavalent vaccine (hexa-wP)

As of October 2026, the UNICEF price per dose for countries eligible for Gavi pricing is US$ 2.85 in the 10-dose presentation.^{Go to footnote 44}

For different groupings of middle-income countries (MICs), the UNICEF price per dose For SII's hexa-wP vaccine ranges from US$ 3.00 in the 10-dose to US$ 4.50 in the single dose presentations.^{Go to footnote 44}

UNICEF prices are subject to change. The latest vaccine price information is available from UNICEF Supply Division.^{Go to footnote 44} 

The 2026 PAHO Revolving Fund vaccines pricelist reports a price per dose ranging from US$ 2.85 in the 10-dose to US$ 4.5 in the single-dose presentation.^{Go to footnote 55}

For fully self-financing MICs, the country-reported price for 2025 per dose ranges from US$ 21.05 to US$ 39.73 depending on supplier and presentation.^{Go to footnote 66}

Pentavalent vaccine (penta-wP)

As of January 2026, the UNICEF price per dose for countries eligible for Gavi pricing ranges from US$ 0.78 in the 10-dose to US$ 1.26 in the single-dose, depending on supplier.^{Go to footnote 77}

UNICEF prices are subject to change. The latest vaccine price information is available from UNICEF Supply Division.^{Go to footnote 77} 

The 2026 PAHO Revolving Fund vaccines pricelist reports a price per dose ranging from US$ 1.31 to US$ 4.15 depending on supplier and presentation.^{Go to footnote 55}

For fully self-financing MICs, the country-reported price for 2025 per dose ranges from US$ 1.21 to US$ 4.96 depending on supplier and presentation.^{Go to footnote 66}

IPV vaccine

As of April 2026, the UNICEF prices per dose for countries accessing Gavi prices ranges from US$ 1.04 in the 5-dose presentation to US$ 2.8, in the single-dose presentation depending on supplier.^{Go to footnote 88}

UNICEF price for self-procuring MICs is €3.5 per dose.^{Go to footnote 88}

The 2026 PAHO Revolving Fund vaccines pricelist reports a price per dose ranging from US$ 1.18 to US$ 1.98 depending on supplier and presentation.^{Go to footnote 66}

For fully self-financing MICs, the country-reported prices per dose for 2025 range from US$ 2.05 to US$ 12.33 depending on supplier and presentation.^{Go to footnote 66}

In European countries with vaccine procurement through public tenders the price per child vaccinated with standard vaccines ranged from €59 to €117 when using pentavalent and from €98 to €220 when using hexa-aP vaccines.^{Go to footnote 99}

A 2022 study focused on Peru estimated the total cost of fully vaccinating a child with the hexa-aP vaccine at $126.42, compared to US$ 116.27 under the existing schedule using the current scheme using the wP-containing pentavalent vaccines with IPV and OPV.^{Go to footnote 1010}

While hexavalent vaccines may have higher upfront costs, they can help reduce logistical challenges and overall societal burden, offering potential economic and practical benefits for immunization programs. The magnitude and direction of costs and savings are context dependent and vary according to current pentavalent and IPV vaccine presentations, wastage, cold-chain requirements, delivery platform, co-financing status, and whether the programme currently uses one or two IPV doses.

Studies from Peru (penta-wP compared to hexa-aP), Argentina (penta –wP compared to hexa-aP), Colombia (aP compared to hexa-wP), and South Korea (DTaP-IPV-Hib-HepB compared to DTaP-IPV/Hib) have reported potential economic and operational benefits of hexavalent vaccine use in specific programme contexts.^{Go to footnote 1111, Go to footnote 1212, Go to footnote 1313, Go to footnote 1414, Go to footnote 1515, Go to footnote 1616, Go to footnote 1717}

Cost–effectiveness varies considerably by several factors, including, the burden of disease, vaccination coverage, vaccine price, delivery costs, delivery approaches, and schedules. Caution is recommended when comparing estimates of cost-effectiveness for different interventions evaluated by different methods and in different contexts (e.g., with different concurrent health interventions and standards of care).

Scope of Gavi support: Hexavalent is supported by the guaranteed vaccine budget. All Gavi-eligible countries that have not yet introduced hexavalent into their national vaccination schedule are eligible for support for the three-dose whole-cell pertussis (wP) hexavalent vaccine. Adoption of hexavalent vaccine is implemented as a replacement for the existing pentavalent and IPV schedules. Gavi does not support procurement of routine bOPV.^{Go to footnote 1818}

Specific requirements for funding request: Within the holistic application, explain the timing and process of switching from pentavalent and IPV to hexavalent. Countries should allow 6–12 months between decision and planned launch.^{Go to footnote 1818}

Special co-financing considerations: Co-financing calculations will include a subsidy equivalent to the country’s IPV eligibility (one or two doses), based on the annual weighted average price of IPV. Fully self-financing lower-middle income countries (LMICs) are eligible for a temporary subsidy in 2026 to purchase hexavalent vaccines equivalent to their IPV eligibility (one or two doses), aligned with the annual weighted average IPV price. This subsidy will be reduced by 50% in 2027, and by 2028 LMICs will be required to fully finance their hexavalent vaccination programmes. For initial self-financing countries using ten‑dose pentavalent vials, switching to hexavalent is cost‑neutral, as both vaccines are co‑financed at US$ 0.20 per dose.^{Go to footnote 1818}